The role of genetic and epigenetic factors in tumor initiation and progression is well
documented. Histone deacetylases (HDACs), histone methyl transferases (HMTs), and DNA …

Cancers that appear pathologically similar often respond differently to the same drug
regimens. Methods to better match patients to drugs are in high demand. We demonstrate a …

The present invention relates to peptides, proteins, nucleic acids and cells for use in
immunotherapeutic methods. In particular, the present invention relates to the immuno …

The present invention relates to peptides, proteins, nucleic acids and cells for use in
immunotherapeutic methods. In particular, the present invention relates to the immuno …

Cancer metastasis remains a significant challenge and the leading cause of cancer-
associated deaths. It is postulated that during metastasis cells undergo epithelial-to …

T-cell acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) are highly
aggressive malignant tumors. With the current intensive treatment regimens, event-free …

Abstract The P2RY8-CRLF2 and IGH-CRLF2 rearrangements induce the overexpression of
cytokine receptor-like factor 2 (CRLF2) and have been associated with relapse and poor …

Uncontrolled proliferation is a key feature of tumor progression and malignancy. This
suggests that cell-cycle related factors could be exploited as cancer biomarkers and that …

Background Epithelial-to-mesenchymal transition (EMT) is a developmental program that
consists of the loss of epithelial features concomitant with the acquisition of mesenchymal …

Glioblastoma multiforme (GBM) is the most aggressive brain tumor and has a poor
prognosis and is poorly sensitive to radiotherapy or temozolomide (TMZ) chemotherapy …